In Vivo CAR-T Therapy Market Size to Hit USD 10,841.07 Million by 2035

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis

4.3.2. Sales and Distribution Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on In Vivo CAR-T Therapy Market

5.1. COVID-19 Landscape: In Vivo CAR-T Therapy Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global In Vivo CAR-T Therapy Market, By Vector Type

8.1. In Vivo CAR-T Therapy Market, by Vector Type

8.1.1. Viral Vector-based In Vivo CAR-T (AAV, Lentiviral)

8.1.1.1. Market Revenue and Forecast

8.1.2. Non-Viral Vector-based In Vivo CAR-T (LNPs, Electroporation, Nanoparticles)

8.1.2.1. Market Revenue and Forecast

Chapter 9. Global In Vivo CAR-T Therapy Market, By CD19

9.1. In Vivo CAR-T Therapy Market, by Target Antigen

9.1.1. CD19

9.1.1.1. Market Revenue and Forecast

9.1.2. BCMA

9.1.2.1. Market Revenue and Forecast

9.1.3. CD20

9.1.3.1. Market Revenue and Forecast

9.1.4. Solid Tumor Targets (HER2, EGFR, Mesothelin, etc.)

9.1.4.1. Market Revenue and Forecast

Chapter 10. Global In Vivo CAR-T Therapy Market, By Application

10.1. In Vivo CAR-T Therapy Market, by Application

10.1.1. Hematologic Malignancies (Leukemia, Lymphoma, Myeloma)

10.1.1.1. Market Revenue and Forecast

10.1.2. Solid Tumors

10.1.2.1. Market Revenue and Forecast

10.1.3. Autoimmune Diseases

10.1.3.1. Market Revenue and Forecast

Chapter 11. Global In Vivo CAR-T Therapy Market, By Delivery Method

11.1. In Vivo CAR-T Therapy Market, by Delivery Method

11.1.1. Systemic Delivery (Intravenous)

11.1.1.1. Market Revenue and Forecast

11.1.2. Localized Delivery (Intratumoral, Targeted Delivery)

11.1.2.1. Market Revenue and Forecast

Chapter 12. Global In Vivo CAR-T Therapy Market, By End-Use

12.1. In Vivo CAR-T Therapy Market, by End-Use

12.1.1. Hospitals

12.1.1.1. Market Revenue and Forecast

12.1.2. Specialized Cancer Treatment Centers

12.1.2.1. Market Revenue and Forecast

12.1.3. Academic & Research Institutes

12.1.3.1. Market Revenue and Forecast

Chapter 13. Global In Vivo CAR-T Therapy Market, By Development Stage

13.1. In Vivo CAR-T Therapy Market, by Development Stage

13.1.1. Preclinical Stage

13.1.1.1. Market Revenue and Forecast

13.1.2. Clinical Stage (Phase I/II/III)

13.1.2.1. Market Revenue and Forecast

13.1.3. Commercialized Therapies

13.1.3.1. Market Revenue and Forecast

Chapter 14. Global In Vivo CAR-T Therapy Market, Regional Estimates and Trend Forecast

14.1. North America

14.1.1. Market Revenue and Forecast, by Vector Type

14.1.2. Market Revenue and Forecast, by Target Antigen

14.1.3. Market Revenue and Forecast, by Application

14.1.4. Market Revenue and Forecast, by Delivery Method

14.1.5. Market Revenue and Forecast, by End-Use

14.1.6. Market Revenue and Forecast, by Development Stage

14.1.7. U.S.

14.1.7.1. Market Revenue and Forecast, by Vector Type

14.1.7.2. Market Revenue and Forecast, by Target Antigen

14.1.7.3. Market Revenue and Forecast, by Application

14.1.7.4. Market Revenue and Forecast, by Delivery Method

14.1.8. Market Revenue and Forecast, by End-Use

14.1.8.1. Market Revenue and Forecast, by Development Stage

14.1.9. Rest of North America

14.1.9.1. Market Revenue and Forecast, by Vector Type

14.1.9.2. Market Revenue and Forecast, by Target Antigen

14.1.9.3. Market Revenue and Forecast, by Application

14.1.9.4. Market Revenue and Forecast, by Delivery Method

14.1.10. Market Revenue and Forecast, by End-Use

14.1.11. Market Revenue and Forecast, by Development Stage

14.2. Europe

14.2.1. Market Revenue and Forecast, by Vector Type

14.2.2. Market Revenue and Forecast, by Target Antigen

14.2.3. Market Revenue and Forecast, by Application

14.2.4. Market Revenue and Forecast, by Delivery Method

14.2.5. Market Revenue and Forecast, by End-Use

14.2.6. Market Revenue and Forecast, by Development Stage

14.2.8. UK

14.2.8.1. Market Revenue and Forecast, by Vector Type

14.2.8.2. Market Revenue and Forecast, by Target Antigen

14.2.8.3. Market Revenue and Forecast, by Application

14.2.9. Market Revenue and Forecast, by Delivery Method

14.2.10. Market Revenue and Forecast, by End-Use

14.2.10.1. Market Revenue and Forecast, by Development Stage

14.2.11. Germany

14.2.11.1. Market Revenue and Forecast, by Vector Type

14.2.11.2. Market Revenue and Forecast, by Target Antigen

14.2.11.3. Market Revenue and Forecast, by Application

14.2.12. Market Revenue and Forecast, by Delivery Method

14.2.13. Market Revenue and Forecast, by End-Use

14.2.14. Market Revenue and Forecast, by Development Stage

14.2.15. France

14.2.15.1. Market Revenue and Forecast, by Vector Type

14.2.15.2. Market Revenue and Forecast, by Target Antigen

14.2.15.3. Market Revenue and Forecast, by Application

14.2.15.4. Market Revenue and Forecast, by Delivery Method

14.2.16. Market Revenue and Forecast, by End-Use

14.2.16.1. Market Revenue and Forecast, by Development Stage

14.2.17. Rest of Europe

14.2.17.1. Market Revenue and Forecast, by Vector Type

14.2.17.2. Market Revenue and Forecast, by Target Antigen

14.2.17.3. Market Revenue and Forecast, by Application

14.2.17.4. Market Revenue and Forecast, by Delivery Method

14.2.18. Market Revenue and Forecast, by End-Use

14.2.18.1. Market Revenue and Forecast, by Development Stage

14.3. APAC

14.3.1. Market Revenue and Forecast, by Vector Type

14.3.2. Market Revenue and Forecast, by Target Antigen

14.3.3. Market Revenue and Forecast, by Application

14.3.4. Market Revenue and Forecast, by Delivery Method

14.3.5. Market Revenue and Forecast, by End-Use

14.3.6. Market Revenue and Forecast, by Development Stage

14.3.7. India

14.3.7.1. Market Revenue and Forecast, by Vector Type

14.3.7.2. Market Revenue and Forecast, by Target Antigen

14.3.7.3. Market Revenue and Forecast, by Application

14.3.7.4. Market Revenue and Forecast, by Delivery Method

14.3.8. Market Revenue and Forecast, by End-Use

14.3.9. Market Revenue and Forecast, by Development Stage

14.3.10. China

14.3.10.1. Market Revenue and Forecast, by Vector Type

14.3.10.2. Market Revenue and Forecast, by Target Antigen

14.3.10.3. Market Revenue and Forecast, by Application

14.3.10.4. Market Revenue and Forecast, by Delivery Method

14.3.11. Market Revenue and Forecast, by End-Use

14.3.11.1. Market Revenue and Forecast, by Development Stage

14.3.12. Japan

14.3.12.1. Market Revenue and Forecast, by Vector Type

14.3.12.2. Market Revenue and Forecast, by Target Antigen

14.3.12.3. Market Revenue and Forecast, by Application

14.3.12.4. Market Revenue and Forecast, by Delivery Method

14.3.12.5. Market Revenue and Forecast, by End-Use

14.3.12.6. Market Revenue and Forecast, by Development Stage

14.3.13. Rest of APAC

14.3.13.1. Market Revenue and Forecast, by Vector Type

14.3.13.2. Market Revenue and Forecast, by Target Antigen

14.3.13.3. Market Revenue and Forecast, by Application

14.3.13.4. Market Revenue and Forecast, by Delivery Method

14.3.13.5. Market Revenue and Forecast, by End-Use

14.3.13.6. Market Revenue and Forecast, by Development Stage

14.4. MEA

14.4.1. Market Revenue and Forecast, by Vector Type

14.4.2. Market Revenue and Forecast, by Target Antigen

14.4.3. Market Revenue and Forecast, by Application

14.4.4. Market Revenue and Forecast, by Delivery Method

14.4.5. Market Revenue and Forecast, by End-Use

14.4.6. Market Revenue and Forecast, by Development Stage

14.4.7. GCC

14.4.7.1. Market Revenue and Forecast, by Vector Type

14.4.7.2. Market Revenue and Forecast, by Target Antigen

14.4.7.3. Market Revenue and Forecast, by Application

14.4.7.4. Market Revenue and Forecast, by Delivery Method

14.4.8. Market Revenue and Forecast, by End-Use

14.4.9. Market Revenue and Forecast, by Development Stage

14.4.10. North Africa

14.4.10.1. Market Revenue and Forecast, by Vector Type

14.4.10.2. Market Revenue and Forecast, by Target Antigen

14.4.10.3. Market Revenue and Forecast, by Application

14.4.10.4. Market Revenue and Forecast, by Delivery Method

14.4.11. Market Revenue and Forecast, by End-Use

14.4.12. Market Revenue and Forecast, by Development Stage

14.4.13. South Africa

14.4.13.1. Market Revenue and Forecast, by Vector Type

14.4.13.2. Market Revenue and Forecast, by Target Antigen

14.4.13.3. Market Revenue and Forecast, by Application

14.4.13.4. Market Revenue and Forecast, by Delivery Method

14.4.13.5. Market Revenue and Forecast, by End-Use

14.4.13.6. Market Revenue and Forecast, by Development Stage

14.4.14. Rest of MEA

14.4.14.1. Market Revenue and Forecast, by Vector Type

14.4.14.2. Market Revenue and Forecast, by Target Antigen

14.4.14.3. Market Revenue and Forecast, by Application

14.4.14.4. Market Revenue and Forecast, by Delivery Method

14.4.14.5. Market Revenue and Forecast, by End-Use

14.4.14.6. Market Revenue and Forecast, by Development Stage

14.5. Latin America

14.5.1. Market Revenue and Forecast, by Vector Type

14.5.2. Market Revenue and Forecast, by Target Antigen

14.5.3. Market Revenue and Forecast, by Application

14.5.4. Market Revenue and Forecast, by Delivery Method

14.5.5. Market Revenue and Forecast, by End-Use

14.5.6. Market Revenue and Forecast, by Development Stage

14.5.7. Brazil

14.5.7.1. Market Revenue and Forecast, by Vector Type

14.5.7.2. Market Revenue and Forecast, by Target Antigen

14.5.7.3. Market Revenue and Forecast, by Application

14.5.7.4. Market Revenue and Forecast, by Delivery Method

14.5.8. Market Revenue and Forecast, by End-Use

14.5.8.1. Market Revenue and Forecast, by Development Stage

14.5.9. Rest of LATAM

14.5.9.1. Market Revenue and Forecast, by Vector Type

14.5.9.2. Market Revenue and Forecast, by Target Antigen

14.5.9.3. Market Revenue and Forecast, by Application

14.5.9.4. Market Revenue and Forecast, by Delivery Method

14.5.9.5. Market Revenue and Forecast, by End-Use

14.5.9.6. Market Revenue and Forecast, by Development Stage

Chapter 15. Company Profiles

15.1. Capstan Therapeutics

15.1.1. Company Overview

15.1.2. Product Offerings

15.1.3. Financial Performance

15.1.4. Recent Initiatives

15.2. Interius BioTherapeutics

15.2.1. Company Overview

15.2.2. Product Offerings

15.2.3. Financial Performance

15.2.4. Recent Initiatives

15.3. Umoja Biopharma

15.3.1. Company Overview

15.3.2. Product Offerings

15.3.3. Financial Performance

15.3.4. Recent Initiatives

15.4. Sana Biotechnology, Inc.

15.4.1. Company Overview

15.4.2. Product Offerings

15.4.3. Financial Performance

15.4.4. Recent Initiatives

15.5. Cellectis S.A.

15.5.1. Company Overview

15.5.2. Product Offerings

15.5.3. Financial Performance

15.5.4. Recent Initiatives

15.6. Beam Therapeutics Inc.

15.6.1. Company Overview

15.6.2. Product Offerings

15.6.3. Financial Performance

15.6.4. Recent Initiatives

15.7. Precision BioSciences, Inc.

15.7.1. Company Overview

15.7.2. Product Offerings

15.7.3. Financial Performance

15.7.4. Recent Initiatives

15.8. Poseida Therapeutics, Inc.

15.8.1. Company Overview

15.8.2. Product Offerings

15.8.3. Financial Performance

15.8.4. Recent Initiatives

15.9. CRISPR Therapeutics AG

15.9.1. Company Overview

15.9.2. Product Offerings

15.9.3. Financial Performance

15.9.4. Recent Initiatives

15.10. Intellia Therapeutics, Inc.

15.10.1. Company Overview

15.10.2. Product Offerings

15.10.3. Financial Performance

15.10.4. Recent Initiatives

Chapter 16. Research Methodology

16.1. Primary Research

16.2. Secondary Research

16.3. Assumptions

Chapter 17. Appendix

17.1. About Us

17.2. Glossary of Terms

For questions or customization requests, please reach out to us at sales@precedenceresearch.com

Frequently Asked Questions

Answer : The in vivo CAR-T therapy market size is expected to increase from USD 650.00 million in 2025 to USD 10,841.07 million by 2035.

Answer : The in vivo CAR-T therapy market is expected to grow at a compound annual growth rate (CAGR) of around 32.50% from 2026 to 2035.

Answer : The major players in the in vivo CAR-T therapy market include Capstan Therapeutics, Interius BioTherapeutics, Umoja Biopharma, Sana Biotechnology, Inc., Cellectis S.A., Beam Therapeutics Inc., Precision BioSciences, Inc., Poseida Therapeutics, Inc., CRISPR Therapeutics AG, Intellia Therapeutics, Inc., Novartis AG, Gilead Sciences, Inc. (Kite Pharma), Bristol Myers Squibb Company, Legend Biotech Corporation, and Caribou Biosciences, Inc.

Answer : The driving factors of the in vivo CAR-T therapy market are the rising prevalence of cancer, ongoing advancements in healthcare, and the increasing number of clinical trials focused on in vivo CAR-T therapy.

Answer : North America region will lead the global in vivo CAR-T therapy market during the forecast period 2026 to 2035.